Recent Updates
Recently added Catalysts
ACET Positive Sentiment

Adicet Bio to Participate in Upcoming Investor Conferences

Thursday, October 22, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Adicet Bio, a clinical-stage biotechnology firm, announced its participation in two investor conferences in November. The company is known for developing allogeneic gamma delta CAR-T cell therapies. The first event is the Guggenheim 3rd Annual Healthcare Innovation Conference scheduled for November 9-11, 2026, in Boston.

Market Sentiment Analysis

POSITIVE FACTORS

  • Adicet Bio is participating in notable investor conferences.
  • The company focuses on innovative CAR-T therapies.
  • Engagement in investor conferences may enhance visibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+12%
120-day peak, hindsight
Typical move
1.9%
average across 4 past catalysts
Cash runway
~16 mo
Low dilution risk
Lead asset
ADI-212
Phase 1 · Prostate Cancer Metastatic

Full Press Release Details

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta CAR-T cell and in vivo CAR-T therapies for autoimmune diseases, hematologic malignancies and solid tumors, today announced that company management will participate in two upcoming investor conferences in November. Details of the events are as follows: Guggenheim 3rd Annual Healthcare Innovation Conference, November 9-11, 2026, Boston, M

Frequently Asked Questions

What is Adicet Bio's focus area?

Adicet Bio develops allogeneic gamma delta CAR-T therapies.

When are the upcoming investor conferences?

The conferences are scheduled for November 9-11, 2026.

Where will the Guggenheim conference be held?

The Guggenheim conference will take place in Boston.

What is the significance of these conferences?

These conferences may enhance Adicet Bio's visibility.

ShareAdd on Google
Tags: ACET Adicet Bio investor conferences CAR-T therapies biotechnology
Last updated: Oct 22, 2026

Biotech snapshot

Cash runway
$118M liquidity · $7M/mo burn
~16 mo
Low dilution risk
Lead asset
ADI-212Phase 1
Prostate Cancer Metastatic →

Catalyst track record

+12%
best trade around ACET's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for ACET.

See every catalyst's timing & PoA →